These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37522012)

  • 21. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease.
    Yin J; Kheirkhah A; Dohlman T; Saboo U; Dana R
    Am J Ophthalmol; 2018 Jun; 190():17-23. PubMed ID: 29572107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.
    Chen D; Zhang S; Bian A; Hong J; Deng Y; Zhang M; Chen W; Shao Y; Zhao J
    Medicine (Baltimore); 2019 Aug; 98(31):e16710. PubMed ID: 31374063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain.
    Zhao L; Chen J; Duan H; Yang T; Ma B; Zhou Y; Bian L; Cai X; Qi H
    BMC Ophthalmol; 2024 Jan; 24(1):28. PubMed ID: 38247010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study.
    Leonardi A; Doan S; Amrane M; Ismail D; Montero J; Németh J; Aragona P; Bremond-Gignac D;
    Ophthalmology; 2019 May; 126(5):671-681. PubMed ID: 30593775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corneal permeability changes in dry eye disease: an observational study.
    Fujitani K; Gadaria N; Lee KI; Barry B; Asbell P
    BMC Ophthalmol; 2016 May; 16(1):53. PubMed ID: 27177442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program.
    Pisella PJ; Labetoulle M; Doan S; Cochener-Lamard B; Amrane M; Ismail D; Creuzot-Garcher C; Baudouin C
    Clin Ophthalmol; 2018; 12():289-299. PubMed ID: 29440872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation and Level of Agreement between the Ocular Surface Disease Index and the Symptom Assessment in Dry Eye Questionnaires: A Survey-Based Study.
    Rodriguez-Garcia A; Ruiz-Lozano RE; Bustamante-Arias A; Pantaleon-Garcia J; Hernandez-Quintela E; Navas A
    Curr Eye Res; 2023 Sep; 48(9):788-798. PubMed ID: 37140549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Controlled Trial Comparing Tearcare
    Ayres BD; Bloomenstein MR; Loh J; Chester T; Saenz B; Echegoyen J; Kannarr SR; Perez VL; Rodriguez TC; Dickerson JE
    Clin Ophthalmol; 2023; 17():3925-3940. PubMed ID: 38143559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
    Ozen S; Ozer MA; Akdemir MO
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1173-1177. PubMed ID: 28299439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease.
    Midorikawa-Inomata A; Inomata T; Nojiri S; Nakamura M; Iwagami M; Fujimoto K; Okumura Y; Iwata N; Eguchi A; Hasegawa H; Kinouchi H; Murakami A; Kobayashi H
    BMJ Open; 2019 Nov; 9(11):e033940. PubMed ID: 31772113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review.
    Tong L; Sun CC; Yoon KC; Lim Bon Siong R; Puangsricharern V; Baudouin C
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1606-1615. PubMed ID: 32469256
    [No Abstract]   [Full Text] [Related]  

  • 33. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
    Prabhasawat P; Tesavibul N; Mahawong W
    Cornea; 2012 Dec; 31(12):1386-93. PubMed ID: 23135530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mask-Associated Dry Eye During COVID-19 Pandemic-How Face Masks Contribute to Dry Eye Disease Symptoms.
    Krolo I; Blazeka M; Merdzo I; Vrtar I; Sabol I; Petric-Vickovic I
    Med Arch; 2021 Apr; 75(2):144-148. PubMed ID: 34219875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD.
    Amparo F; Shikari H; Saboo U; Dana R
    Ocul Surf; 2018 Jul; 16(3):377-381. PubMed ID: 29763694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
    Park CH; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Lee HK; Chung TY; Choi CY; Kim HS
    Korean J Ophthalmol; 2019 Aug; 33(4):343-352. PubMed ID: 31389210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
    Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
    JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
    Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
    BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.